| Year |
Citation |
Score |
| 2024 |
Murayama T, Mahadevan NR, Meador CB, Ivanova EV, Pan Y, Knelson EH, Tani T, Nakayama J, Ma X, Thai TC, Hung YP, Kim W, Watanabe H, Cai K, Hata AN, ... Paweletz CP, et al. Targeting TREX1 induces innate immune response in drug-resistant Small Cell Lung Cancer. Cancer Research Communications. PMID 39177280 DOI: 10.1158/2767-9764.CRC-24-0360 |
0.345 |
|
| 2023 |
Odintsov I, Makarem M, Nishino M, Bachert SE, Zhang T, LoPiccolo J, Paweletz CP, Gokhale PC, Ivanova E, Saldanha A, Rudin CM, Lockwood WW, Ladanyi M, Somwar R, Jänne PA, et al. Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 38154514 DOI: 10.1016/j.jtho.2023.12.019 |
0.311 |
|
| 2023 |
Lechner A, Rai A, Rojas-Rudilla V, Kuang Y, Paweletz CP, Sholl LM, Dong F. Atypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer. Archives of Pathology & Laboratory Medicine. PMID 37639432 DOI: 10.5858/arpa.2023-0088-OA |
0.319 |
|
| 2023 |
Paweletz CP, Heavey GA, Kuang Y, Durlacher E, Kheoh T, Chao RC, Spira AI, Leventakos K, Johnson ML, Ou SI, Riely GJ, Anderes K, Yang W, Christensen JG, Janne PA. Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37279096 DOI: 10.1158/1078-0432.CCR-23-0795 |
0.337 |
|
| 2022 |
Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated G12C. The New England Journal of Medicine. PMID 36546659 DOI: 10.1056/NEJMoa2212419 |
0.31 |
|
| 2022 |
Yoshida R, Saigi M, Tani T, Springer BF, Shibata H, Kitajima S, Mahadevan NR, Campisi M, Kim W, Kobayashi Y, Thai TC, Haratani K, Yamamoto Y, Sundararaman SK, Knelson EH, ... ... Paweletz CP, et al. MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer. Cancer Research. PMID 36066413 DOI: 10.1158/0008-5472.CAN-22-0770 |
0.345 |
|
| 2022 |
Williamson DFK, Marris SRN, Rojas-Rudilla V, Bruce JL, Paweletz CP, Oxnard GR, Sholl LM, Dong F. Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR. Plos One. 17: e0264201. PMID 35202431 DOI: 10.1371/journal.pone.0264201 |
0.368 |
|
| 2021 |
Haikala HM, Lopez T, Köhler J, Eser PO, Xu M, Zeng Q, Teceno TJ, Ngo K, Zhao Y, Ivanova EV, Bertram AA, Leeper BA, Chambers ES, Adeni AE, Taus LJ, ... ... Paweletz CP, et al. EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody drug conjugate HER3-DXd. Cancer Research. PMID 34548332 DOI: 10.1158/0008-5472.CAN-21-2426 |
0.303 |
|
| 2021 |
Cheng ML, Lau CJ, Milan MSD, Supplee JG, Riess JW, Bradbury PA, Jänne PA, Oxnard GR, Paweletz CP. Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. Jco Precision Oncology. 5. PMID 34250387 DOI: 10.1200/PO.20.00419 |
0.312 |
|
| 2020 |
Campisi M, Sundararaman SK, Shelton SE, Knelson EH, Mahadevan NR, Yoshida R, Tani T, Ivanova E, Cañadas I, Osaki T, Lee SWL, Thai T, Han S, Piel BP, Gilhooley S, ... Paweletz CP, et al. Tumor-Derived cGAMP Regulates Activation of the Vasculature. Frontiers in Immunology. 11: 2090. PMID 33013881 DOI: 10.3389/Fimmu.2020.02090 |
0.368 |
|
| 2020 |
Sholl LM, Oxnard GR, Paweletz CP. Traditional Diagnostics versus Disruptive Technology: The role of the pathologist in the era of liquid biopsy. Cancer Research. PMID 32606002 DOI: 10.1158/0008-5472.Can-20-0134 |
0.374 |
|
| 2020 |
Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, et al. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nature Communications. 11: 2350. PMID 32393766 DOI: 10.1038/S41467-020-16170-3 |
0.386 |
|
| 2020 |
Ivanova E, Kuraguchi M, Xu M, Portell A, Taus LJ, Diala I, Lalani AS, Choi J, Chambers ES, Li S, Liu S, Chen T, Barbie TU, Oxnard GR, Haworth J, ... ... Paweletz CP, et al. Use of ex vivo patient derived tumor organotypic spheroids to identify combination therapies for HER2mutant non small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32034078 DOI: 10.1158/1078-0432.Ccr-19-1844 |
0.439 |
|
| 2020 |
Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, Lo YC, Li YY, Lamberti G, Nguyen T, Milan MSD, Venkatraman D, Umeton R, Paweletz CP, Albayrak A, et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32034073 DOI: 10.1158/1078-0432.Ccr-19-3608 |
0.368 |
|
| 2020 |
Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, Portell A, Lizotte PH, Ficarro SB, Li S, Chen T, ... ... Paweletz CP, et al. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 37: 104-122.e12. PMID 31935369 DOI: 10.1016/J.Ccell.2019.12.006 |
0.435 |
|
| 2020 |
Rotow JK, Costa DB, Paweletz CP, Awad MM, Marcoux P, Rangachari D, Barbie DA, Sands J, Cheng ML, Johnson BE, Oxnard GR, Jackman DM, Kwiatkowski DJ, Kehl KL, Izdebski MD, et al. Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 38: 9507-9507. DOI: 10.1200/Jco.2020.38.15_Suppl.9507 |
0.415 |
|
| 2020 |
Liu JF, Doshi KA, Lee BH, Peluso MO, Zhang L, Zhou S, Zeng Q, Wang S, Kirschmeier PT, Tran CA, Paweletz C, Rausch M, Paterson AM, Gokhale PC, Matulonis UA. Abstract 4515: The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer Immunology. DOI: 10.1158/1538-7445.Am2020-4515 |
0.317 |
|
| 2019 |
Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, Triplett O, Mariño-Enríquez A, Wagner AJ, Demetri GD, Velculescu VE, Paweletz CP, Fletcher JA, George S. Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31471313 DOI: 10.1158/1078-0432.Ccr-19-2150 |
0.409 |
|
| 2019 |
Stinchcombe TE, Jänne PA, Wang X, Bertino EM, Weiss J, Bazhenova L, Gu L, Lau C, Paweletz C, Jaslowski A, Gerstner GJ, Baggstrom MQ, Graziano S, Bearden J, Vokes EE. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. Jama Oncology. PMID 31393548 DOI: 10.1001/Jamaoncol.2019.1847 |
0.428 |
|
| 2019 |
Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA, Costa DB. Brief Report: EGFR-mutated lung cancers resistant to osimertinib through EGFR-C797S respond to 1 generation reversible EGFR inhibitors but eventually acquire EGFR-T790M/C797S in preclinical models and clinical samples. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31377341 DOI: 10.1016/J.Jtho.2019.07.016 |
0.422 |
|
| 2019 |
Rashidian M, LaFleur MW, Verschoor VL, Dongre A, Zhang Y, Nguyen TH, Kolifrath S, Aref AR, Lau CJ, Paweletz CP, Bu X, Freeman GJ, Barrasa MI, Weinberg RA, Sharpe AH, et al. Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. Proceedings of the National Academy of Sciences of the United States of America. PMID 31375632 DOI: 10.1073/Pnas.1905005116 |
0.324 |
|
| 2019 |
Hanna GJ, Lau CJ, Mahmood U, Supplee JG, Mogili AR, Haddad RI, Jänne PA, Paweletz CP. Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncology. 95: 120-126. PMID 31345379 DOI: 10.1016/J.Oraloncology.2019.06.019 |
0.344 |
|
| 2019 |
Supplee JG, Milan MSD, Lim LP, Potts KT, Sholl LM, Oxnard GR, Paweletz CP. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. Lung Cancer (Amsterdam, Netherlands). 134: 96-99. PMID 31320002 DOI: 10.1016/J.Lungcan.2019.06.004 |
0.438 |
|
| 2019 |
Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, Razavi P, Reis-Filho JS, Shen R, Isbell JM, Blocker AW, Eattock N, Gnerre S, Satya RV, Xu H, ... ... Paweletz CP, et al. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30891595 DOI: 10.1093/Annonc/Mdz046 |
0.481 |
|
| 2019 |
Riess JW, Groshen SG, Reckamp KL, Wakelee HA, Oxnard GR, Padda SK, Koczywas M, Piotrowska Z, Sholl LM, Paweletz CP, Lau CJ, Kolesar J, Mack PC, Moscow J, Janne PA, et al. Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study. Journal of Clinical Oncology. 37: 9057-9057. DOI: 10.1200/Jco.2019.37.15_Suppl.9057 |
0.404 |
|
| 2019 |
Hanna GJ, Lau CJ, Mahmood U, Haddad RI, Paweletz CP, Janne PA. Abstract 452: Salivary HPV cell free DNA levels predict locoregional disease burden and response in oropharyngeal cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-452 |
0.316 |
|
| 2019 |
Portell AJ, Greene J, Taus LJ, Lizotte P, Ivanova E, Menezes KO, Aref AR, Kirschmeier P, Jenkins RW, Barbie D, Paweletz CP. Abstract 1483: Ex vivo single cell RNA-sequencing of tumor derived organotypic spheroids identifies a unique mesenchymal resistance program to PD-1 blockade Cancer Research. 79: 1483-1483. DOI: 10.1158/1538-7445.Am2019-1483 |
0.397 |
|
| 2019 |
Supplee JG, Milan MS, Potts KT, Sholl LM, Shaffer TS, Lim LP, Janne PA, Oxnard GR, Paweletz CP. Abstract 1374: Building an effective concordance study: Plasma Next Generation Sequencing (NGS) for oncogenic fusion detection in non-small cell lung carcinoma (NSCLC) Cancer Research. 79: 1374-1374. DOI: 10.1158/1538-7445.Am2019-1374 |
0.45 |
|
| 2019 |
Larios D, Ivanova E, Aref A, Portell A, Rienzo AD, Barbie D, Paweletz C, Bueno R. MA12.06 Patient-Derived Organotypic Tumor Spheroids (PDOTS) Facilitate Therapeutic Screening for Malignant Pleural Mesothelioma Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.596 |
0.317 |
|
| 2018 |
Stinchcombe TE, Janne PA, Wang X, Bertino EM, Weiss JM, Bazhenova L, Gu L, Lau CJ, Paweletz CP, Jaslowski AJ, Gerstner GJ, Baggstrom MQ, Graziano SL, Bearden J, Vokes EE. A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii522. PMID 32137355 DOI: 10.1093/Annonc/Mdy292.066 |
0.409 |
|
| 2018 |
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, ... ... Paweletz CP, et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 175: 998-1013.e20. PMID 30388456 DOI: 10.1016/J.Cell.2018.10.038 |
0.38 |
|
| 2018 |
Barbie DA, Kitajima S, Ivanova E, Guo S, Yoshida R, Campisi M, Sundararaman SK, Tange S, Mitsuishi Y, Thai TC, Masuda S, Piel BP, Sholl LM, Kirschmeier PT, Paweletz CP, et al. Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Discovery. PMID 30297358 DOI: 10.1158/2159-8290.Cd-18-0689 |
0.407 |
|
| 2018 |
Fitarelli-Kiehl M, Yu F, Ashtaputre R, Leong KW, Ladas I, Supplee J, Paweletz C, Mitra D, Schoenfeld JD, Parangi S, Makrigiorgos GM. Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies. Clinical Chemistry. PMID 30274976 DOI: 10.1373/Clinchem.2018.293845 |
0.373 |
|
| 2018 |
Aref AR, Campisi M, Ivanova E, Portell A, Larios D, Piel BP, Mathur N, Zhou C, Coakley RV, Bartels A, Bowden M, Herbert Z, Hill S, Gilhooley S, Carter J, ... ... Paweletz CP, et al. 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab On a Chip. PMID 30183789 DOI: 10.1039/C8Lc00322J |
0.392 |
|
| 2018 |
Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. Jama Oncology. PMID 30073261 DOI: 10.1001/Jamaoncol.2018.2969 |
0.445 |
|
| 2018 |
Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova E, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, et al. Amplification of wild type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30072474 DOI: 10.1158/1078-0432.Ccr-18-0876 |
0.428 |
|
| 2018 |
Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, ... ... Paweletz CP, et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nature Medicine. PMID 30038220 DOI: 10.1038/S41591-018-0116-5 |
0.378 |
|
| 2018 |
Guibert N, Tsukada H, Hwang DH, Chambers E, Cibas ES, Bale T, Supplee J, Ulrich B, Sholl LM, Paweletz CP, Oxnard GR. Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping. Lung Cancer (Amsterdam, Netherlands). 122: 72-75. PMID 30032849 DOI: 10.1016/J.Lungcan.2018.05.024 |
0.405 |
|
| 2018 |
Oxnard GR, Paweletz CP. Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. Jama Oncology. PMID 30027282 DOI: 10.1001/Jamaoncol.2018.2311 |
0.306 |
|
| 2018 |
Hanna GJ, Supplee JG, Kuang Y, Mahmood U, Lau CJ, Haddad RI, Jänne PA, Paweletz CP. Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30010779 DOI: 10.1093/Annonc/Mdy251 |
0.325 |
|
| 2018 |
Li S, Liu S, Deng J, Akbay EA, Hai J, Ambrogio C, Zhang L, Zhou F, Jenkins RW, Adeegbe DO, Gao P, Wang X, Paweletz CP, Herter-Sprie GS, Chen T, et al. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29945997 DOI: 10.1158/1078-0432.Ccr-17-3438 |
0.442 |
|
| 2018 |
Kuang Y, O'Connell A, Sacher AG, Feeney N, Alden RS, Oxnard GR, Paweletz CP. Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR. Methods in Molecular Biology (Clifton, N.J.). 1768: 193-207. PMID 29717445 DOI: 10.1007/978-1-4939-7778-9_12 |
0.421 |
|
| 2018 |
Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, Fairclough SR, Zill OA, Sikora M, Mokhtari R, Abdueva D, Nagy RJ, Lee CE, Kiedrowski LA, Paweletz CP, et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29691297 DOI: 10.1158/1078-0432.Ccr-17-3831 |
0.366 |
|
| 2018 |
Hu Y, Ulrich B, Supplee J, Kuang Y, Lizotte PH, Feeney N, Guibert N, Awad MM, Wong KK, Janne PA, Paweletz CP, Oxnard GR. False positive plasma genotyping due to clonal hematopoiesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29567812 DOI: 10.1158/1078-0432.Ccr-18-0143 |
0.427 |
|
| 2018 |
Yanagita M, Luke JJ, Hodi FS, Jänne PA, Paweletz CP. Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization. Melanoma Research. PMID 29406397 DOI: 10.1097/Cmr.0000000000000431 |
0.322 |
|
| 2018 |
Guibert N, Hu Y, Feeney N, Kuang Y, Plagnol V, Jones G, Howarth K, Beeler JF, Paweletz CP, Oxnard GR. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29325035 DOI: 10.1093/Annonc/Mdy005 |
0.459 |
|
| 2018 |
Ulrich BC, Paweletz CP. Cell-Free DNA in Oncology: Gearing up for Clinic. Annals of Laboratory Medicine. 38: 1-8. PMID 29071812 DOI: 10.3343/Alm.2018.38.1.1 |
0.416 |
|
| 2018 |
Awad MM, Bahcall M, Sholl LM, Wilson FH, Paweletz C, Capelletti M, Leonardi GC, Watanabe M, Baba H, Chambers ES, Redig AJ, Nishino M, VanderLaan PA, Costa DB, Imamura Y, et al. Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 36: 9069-9069. DOI: 10.1200/Jco.2018.36.15_Suppl.9069 |
0.449 |
|
| 2018 |
Serrano C, Leal A, Phallen J, Marino-Enriquez A, Kuang Y, Triplett O, Morgan JA, Barysauskas C, Wagner AJ, Demetri GD, Velculescu VE, Paweletz C, Fletcher JA, George S. Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology. 36: 11510-11510. DOI: 10.1200/Jco.2018.36.15_Suppl.11510 |
0.392 |
|
| 2018 |
Aref A, Ivanova E, Chambers E, Portell A, Jenkins R, Lin M, Xu M, Haworth J, Bahcall M, Paweletz C, Janne P. Abstract 988: Short-term culture of organotypic tumor spheroids derived from patient xenografts in a novel 3D microfluidic chip predicts in vivo response of targeted therapies Cancer Research. 78: 988-988. DOI: 10.1158/1538-7445.Am2018-988 |
0.472 |
|
| 2018 |
Larios D, Aref A, Ivanova E, Piel B, Portell A, Barbie DA, Bueno R, Paweletz C. Abstract 5025: From OR to bench: Identification of variables affecting success in generating patient derived organotypic spheroids (pDOTS) Cancer Research. 78: 5025-5025. DOI: 10.1158/1538-7445.Am2018-5025 |
0.369 |
|
| 2018 |
Marino-Enriquez A, George S, Supplee J, Heavey G, Janne PA, Raut C, Fletcher J, Demetri GD, Paweletz CP, Kuang Y. Abstract 4578: Development of a rapid clinical grade assay to detect and monitor secondary KIT mutations in circulating free DNA (cfDNA) for personalization of targeted therapy for gastrointestinal stromal tumors (GIST) Cancer Research. 78: 4578-4578. DOI: 10.1158/1538-7445.Am2018-4578 |
0.437 |
|
| 2018 |
Hanna GJ, Supplee JG, Kuang Y, Geary K, Janne PA, Haddad RI, Paweletz CP. Abstract 2581: Plasma HPV cell free DNA as an earlier predictor of treatment response in advanced oropharyngeal cancer Cancer Research. 78: 2581-2581. DOI: 10.1158/1538-7445.Am2018-2581 |
0.315 |
|
| 2017 |
Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, et al. CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation. Cancer Discovery. PMID 29101163 DOI: 10.1158/2159-8290.Cd-17-0915 |
0.344 |
|
| 2017 |
Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, ... ... Paweletz CP, et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery. PMID 29101162 DOI: 10.1158/2159-8290.Cd-17-0833 |
0.347 |
|
| 2017 |
Hu Y, Alden RS, Odegaard JI, Fairclough SR, Chen R, Heng J, Feeney N, Nagy R, Shah J, Ulrich B, Gutierrez M, Lanman RB, Garber JE, Paweletz CP, Oxnard GR. Discrimination of germline EGFR T790M mutations in plasma cell-free DNA allows study of prevalence across 31,414 cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28947568 DOI: 10.1158/1078-0432.Ccr-17-1745 |
0.481 |
|
| 2017 |
Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, Nardone A, De Angelis C, Detre S, Dodson A, Mohammed H, et al. Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proceedings of the National Academy of Sciences of the United States of America. PMID 28507152 DOI: 10.1073/Pnas.1620993114 |
0.351 |
|
| 2017 |
Guibert NM, Paweletz C, Hu Y, Feeney NB, Plagnol V, Poole V, Jones G, Oxnard GR. Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib. Journal of Clinical Oncology. 35: 11529-11529. DOI: 10.1200/Jco.2017.35.15_Suppl.11529 |
0.447 |
|
| 2017 |
Ivanova E, Aref A, Jenkins R, Lizotte P, Huang W, Palakurthi S, Kirschmeier P, Barbie D, Paweletz C, Janne P, Wong K. Abstract LB-218: Validation of a novel microfluidic device for screening of immune checkpoint inhibitors using 3D organotypic tumor spheroids Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-218 |
0.397 |
|
| 2017 |
Shapiro GI, Hilton J, Gandi L, Chau N, Cleary J, Wolanski A, Anderson A, Beardslee B, Hassinger F, Bhushan K, Downey E, Gibson J, Pruitt-Thompson S, Muzikansky A, Barry S, ... ... Paweletz C, et al. Abstract CT046: Phase I dose escalation study of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor PD-0325901 in patients withRASmutant solid tumors Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct046 |
0.36 |
|
| 2017 |
Ulrich BC, Nagy RJ, Odegaard JI, Lanman RB, Oxnard GR, Paweletz CP. Abstract 5692: Cross-platform detection and quantification of actionable mutations in cell-free DNA shows high concordance and correlation between next-generation sequencing and droplet digital PCR Cancer Research. 77: 5692-5692. DOI: 10.1158/1538-7445.Am2017-5692 |
0.453 |
|
| 2017 |
Kuang Y, Siddiqui B, Hu J, Barry WT, Lin NU, Wagle N, Kirschmeier P, Jänne PA, Paweletz C, Krop I, Winer EP, Brown M, Jeselsohn R. Abstract 4950: The emergence of ESR1 mutations is associated with aromatase inhibitor and fulvestrant therapy Cancer Research. 77: 4950-4950. DOI: 10.1158/1538-7445.Am2017-4950 |
0.406 |
|
| 2017 |
Oxnard GR, Hu Y, Tracy P, Feeney N, Paweletz CP, Thress KS, Janne PA. Abstract 4112: Overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquired resistance to osimertinib in T790M-positive NSCLC Cancer Research. 77: 4112-4112. DOI: 10.1158/1538-7445.Am2017-4112 |
0.407 |
|
| 2017 |
Bahcall M, Kuang Y, Paweletz CP, Jänne PA. Abstract 4100: Mechanisms of resistance to type I and type II MET inhibitors in non-small cell lung cancer Cancer Research. 77: 4100-4100. DOI: 10.1158/1538-7445.Am2017-4100 |
0.43 |
|
| 2017 |
Köhler J, Paweletz CP, Kuang Y, Gokhale P, Wilkens MK, Tiv H, Ogino A, Choi J, Kirschmeier PT, Jänne PA. Abstract 372: Optimizing vertical MAPK pathway inhibition for RAS mutant non-small cell lung cancer Cancer Research. 77: 372-372. DOI: 10.1158/1538-7445.Am2017-372 |
0.35 |
|
| 2017 |
Guibert N, Tsukada H, Hwang D, Bale T, Chambers E, Ulrich B, Paweletz C, Sholl L, Oxnard G. MA 20.14 Genotyping of Lung Cancer Using Cell-Free DNA (cfDNA) from Cytologic Supernatant (CSN) Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.653 |
0.393 |
|
| 2017 |
Ivanova E, Bahcall M, Aref A, Chen T, Taus L, Avogadri-Connors F, Cutler R, Lalani A, Choi J, Haworth J, Chambers E, Kuraguchi M, Xu M, Redig A, Wong K, ... Paweletz C, et al. MA 07.12 Short-Term Culture of Patient Derived Tumor Organoids Identify Neratinib/Trastuzumab as an Effective Combination in HER2 Mutant Lung Cancer Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.512 |
0.398 |
|
| 2017 |
Guibert N, Hu Y, Feeney N, Michael E, Woodhouse S, Howarth K, Jones G, Paweletz C, Oxnard G. P3.02-014 Amplicon-Based Next-Generation Sequencing (NGS) of Plasma Cell-Free DNA (cfDNA) for Detection of Driver and Resistance Mutations in NSCLC Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.1544 |
0.402 |
|
| 2016 |
Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, et al. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. The Oncologist. PMID 27789775 DOI: 10.1634/Theoncologist.2016-0229 |
0.374 |
|
| 2016 |
Lizotte PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, Dries R, Almonte C, Herter-Sprie GS, Santos A, Feeney NB, Paweletz CP, Kulkarni MM, Bass AJ, Rustgi AK, et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. Jci Insight. 1: e89014. PMID 27699239 DOI: 10.1172/Jci.Insight.89014 |
0.438 |
|
| 2016 |
Bahcall M, Sim T, Paweletz CP, Patel JD, Alden RS, Kuang Y, Sacher AG, Kim ND, Lydon C, Awad MM, Jaklitsch MT, Sholl LM, Jänne PA, Oxnard GR. Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discovery. PMID 27694386 DOI: 10.1158/2159-8290.Cd-16-0686 |
0.457 |
|
| 2016 |
Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, ... ... Paweletz CP, et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27573169 DOI: 10.1158/1078-0432.Ccr-16-1237 |
0.385 |
|
| 2016 |
Oxnard GR, Paweletz CP, Sholl LM. Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer. Jama Oncology. PMID 27541382 DOI: 10.1001/Jamaoncol.2016.2835 |
0.377 |
|
| 2016 |
Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Jänne PA. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27354477 DOI: 10.1200/Jco.2016.66.7162 |
0.431 |
|
| 2016 |
Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA. A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27281561 DOI: 10.1158/1078-0432.Ccr-16-0909 |
0.472 |
|
| 2016 |
Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Barrett C, Yang J, Jänne P. 135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S154. PMID 27198357 DOI: 10.1016/S1556-0864(16)30328-8 |
0.311 |
|
| 2016 |
Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O’Connell A, Feeney N, Mach SL, Jänne PA, Oxnard GR. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer Jama Oncology. 2: 1014-1022. PMID 27055085 DOI: 10.1001/Jamaoncol.2016.0173 |
0.472 |
|
| 2016 |
Karlovich CA, Goldman J, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel DR, Soria JC, Solomon B, Camidge DR, Gadgeel SM, Paweletz CP, et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase 1 study of rociletinib (CO-1686). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26747242 DOI: 10.1158/1078-0432.Ccr-15-1260 |
0.442 |
|
| 2016 |
Konstantinopoulos P, Palakurthi S, Zeng Q, Zhou S, Liu JF, Ivanova E, Paweletz C, Kommajosyula N, D'Andrea AD, Shapiro G, Matulonis UA. In vivo synergism between PARP-inhibitor olaparib and HSP90-inhibitor AT13387 in high grade serous ovarian cancer patient derived xenografts. Journal of Clinical Oncology. 34: e17045-e17045. DOI: 10.1200/Jco.2016.34.15_Suppl.E17045 |
0.369 |
|
| 2016 |
Duda DG, Ziehr DR, Guo H, Ng M, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova E, Paweletz C, Demeo M, Ramaiya NH, Overmoyer B, Jain RK, Winer EP, et al. Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 34: 1093-1093. DOI: 10.1200/Jco.2016.34.15_Suppl.1093 |
0.36 |
|
| 2016 |
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Weigelt B, Sakr RA, King TA, Chandarlapaty S, Reis-Filho JS, Hanker AB, Arteaga CL, Yeon PS, Michor F, Polyak K. Abstract PR05: The effect of chemotherapy on HER2+ breast cancer heterogeneity measured by STAR-FISH: Detection of PIK3CA mutation and HER2 amplification at single-cell level in situ Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-Pr05 |
0.443 |
|
| 2016 |
Palakurthi S, Xu M, Redig AJ, Dills M, Gokhale P, Choi J, Ogino A, Kuang Y, Feeney N, Paweletz C, Kirscmeier P, English J, Cross D, Jänne P. Abstract 5192: Utilizing NSCLC PDXs derived from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies Cancer Research. 76: 5192-5192. DOI: 10.1158/1538-7445.Am2016-5192 |
0.438 |
|
| 2016 |
Li BT, Janku F, Janne PA, Mills GB, Madwani K, Alden RS, Paweletz CP, Ladanyi M, Aravanis A, Jung B, Gnerre S, Sehnert AJ, Solit DB, Riely GJ, Oxnard GR. Abstract 4342: Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers: results from the Actionable Genome Consortium Cancer Research. 76: 4342-4342. DOI: 10.1158/1538-7445.Am2016-4342 |
0.49 |
|
| 2016 |
Paweletz CP, Oxnard GR, Feeney N, Hilton JF, Gandhi L, Do KT, Anderson A, Wolanski A, Tejeda A, English JM, Kirschmeier PT, Jänne PA, Shapiro GI. Abstract 3157: Serial droplet digital PCR (ddPCR) of plasma cell-free DNA (cfDNA) as pharmacodynamic (PD) biomarker in Phase 1 clinical trials for patients (pts) with KRAS mutant non-small cell lung cancer (NSCLC) Cancer Research. 76: 3157-3157. DOI: 10.1158/1538-7445.Am2016-3157 |
0.416 |
|
| 2015 |
Paweletz CP, Sacher A, Raymond CK, Alden RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English JM, Lim LP, Jänne PA, Oxnard GR. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26459174 DOI: 10.1158/1078-0432.Ccr-15-1627-T |
0.496 |
|
| 2015 |
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nature Genetics. 47: 1212-9. PMID 26301495 DOI: 10.1038/Ng.3391 |
0.384 |
|
| 2015 |
Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker JH, Kikuchi E, Xu C, Patel TB, Al-Shahrour F, Carretero J, Wong KK, Jänne PA, Shapiro GI, Shimamura T. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Research. PMID 26282169 DOI: 10.1158/0008-5472.Can-15-0377 |
0.437 |
|
| 2015 |
Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, et al. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Investigational New Drugs. PMID 26123926 DOI: 10.1007/S10637-015-0269-8 |
0.367 |
|
| 2015 |
Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nature Medicine. 21: 560-2. PMID 25939061 DOI: 10.1038/Nm.3854 |
0.445 |
|
| 2015 |
Castellanos-Rizaldos E, Paweletz C, Song C, Oxnard GR, Mamon H, Jänne PA, Makrigiorgos GM. Enhanced ratio of signals enables digital mutation scanning for rare allele detection. The Journal of Molecular Diagnostics : Jmd. 17: 284-92. PMID 25772705 DOI: 10.1016/J.Jmoldx.2014.12.003 |
0.372 |
|
| 2015 |
Sacher AG, Paweletz C, Alden R, O'Connell A, Mach SL, Janne PA, Oxnard GR. A prospective validation of plasma ddPCR for rapid EGFR and KRAS genotyping of advanced NSCLC patients (pts). Journal of Clinical Oncology. 33: 11089-11089. DOI: 10.1200/Jco.2015.33.15_Suppl.11089 |
0.404 |
|
| 2015 |
Yanagita M, Paweletz C, O'Connell A, Jackman DM, Kuang Y, Oxnard GR, Janne PA. A prospective evaluation of cell free DNA (cfDNA) genotyping and circulating tumor cells (CTC) in EGFR mutant NSCLC patients (pts) treated with erlotinib. Journal of Clinical Oncology. 33: 11068-11068. DOI: 10.1200/Jco.2015.33.15_Suppl.11068 |
0.432 |
|
| 2015 |
Tolaney SM, Ziehr DR, Guo H, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova E, Paweletz C, Demeo M, Ramaiya NH, Overmoyer B, Jain RK, Duda DG, Winer EP. A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 33: 1080-1080. DOI: 10.1200/Jco.2015.33.15_Suppl.1080 |
0.355 |
|
| 2015 |
Oxnard GR, Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Morkovets A, Vivancos A, Kuang Y, Ercan D, Cantarini M, Barrett JC, Janne PA. Abstract LB-123: Analysis of cell-free plasma DNA (cfDNA) identifies 3 molecular subtypes of acquired resistance to AZD9291, a novel EGFR tyrosine kinase inhibitor (TKI), in patients (pts) with advanced lung cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-123 |
0.477 |
|
| 2015 |
Paweletz CP, Raymond CK, Sacher AG, Kuang Y, O'Connell A, Lim L, Li M, Armour C, English JM, Kirschmeier PT, Jänne PA, Oxnard G. Abstract 928: Bias-corrected next generation sequencing of cell free DNA for detection of actionable mutations and rearrangements in advanced non-small cell lung cancer Cancer Research. 75: 928-928. DOI: 10.1158/1538-7445.Am2015-928 |
0.474 |
|
| 2015 |
Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker JH, Kikuchi E, Xu C, Patel TB, Al-shahrour F, Carretero J, Wong K, Janne PA, Shapiro GI, Shimamura T. Abstract 766: Suppression of gefitinib-induced EMT in EGFR mutant NSCLC preferentially selects for acquired T790M Cancer Research. 75: 766-766. DOI: 10.1158/1538-7445.Am2015-766 |
0.433 |
|
| 2015 |
Yanagita M, Luke JJ, Paweletz CP, Ivanova E, Kirschmeier PT, Hodi SF, Jänne PA. Abstract 1598: Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in situ hybridization Cancer Research. 75: 1598-1598. DOI: 10.1158/1538-7445.Am2015-1598 |
0.417 |
|
| 2015 |
Gokhale PC, Palakurthi S, Xu M, Calles A, Shah SD, O'Connell A, Messineo M, Kuang Y, Yanagita M, Ali M, Tran CA, Choi J, Ogino A, Butaney M, Redig AJ, ... Paweletz C, et al. Abstract 1451: Modeling patient-derived lung cancer in mice: Preclinical tool for drug development Cancer Research. 75: 1451-1451. DOI: 10.1158/1538-7445.Am2015-1451 |
0.42 |
|
| 2015 |
Oxnard GR, Sacher AG, Alden RS, Feeney NB, Heng JC, Nagy RJ, Lanman RB, Paweletz CP, Janne PA. Abstract B104: Differentiating somatic and germline variants using targeted next-generation sequencing (NGS) of cell-free plasma DNA (cfDNA) Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B104 |
0.466 |
|
| 2015 |
Palakurthi SS, Xu M, Redig A, Dills M, Gokhale P, Choi J, Ogino A, Kuang Y, Feeney N, Paweletz C, Kirschmeier P, English J, Cross D, Janne PA. Abstract A105: Credentialing the concept of “co-clinical trials”: Utility of lung cancer PDX models derived from patients on AZD9291 clinical trials Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A105 |
0.459 |
|
| 2014 |
Jänne PA, Ou SH, Kim DW, Oxnard GR, Martins R, Kris MG, Dunphy F, Nishio M, O'Connell J, Paweletz C, Taylor I, Zhang H, Goldberg Z, Mok T. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. The Lancet. Oncology. 15: 1433-41. PMID 25456362 DOI: 10.1016/S1470-2045(14)70461-9 |
0.456 |
|
| 2014 |
Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, Johnson BE. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. Journal of the National Cancer Institute. 106. PMID 25106647 DOI: 10.1093/Jnci/Dju214 |
0.428 |
|
| 2014 |
Paweletz CP, Jänne PA. Monitoring cancer through the blood. Cancer. 120: 3859-61. PMID 25103496 DOI: 10.1002/Cncr.28967 |
0.512 |
|
| 2014 |
Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1698-705. PMID 24429876 DOI: 10.1158/1078-0432.Ccr-13-2482 |
0.512 |
|
| 2014 |
Sacher AG, Oxnard GR, Mach SL, Melissa MM, Jackman DM, Janne PA, Paweletz C. Prediction of lung cancer genotype noninvasively using droplet digital PCR (ddPCR) analysis of cell-free plasma DNA (cfDNA). Journal of Clinical Oncology. 32: 8059-8059. DOI: 10.1200/Jco.2014.32.15_Suppl.8059 |
0.433 |
|
| 2014 |
Tolaney SM, Guo H, Barry WT, Larrabee K, Brock JE, Wagle N, Allen EMV, Paweletz C, Ivanova E, Janne PA, Overmoyer B, Wright JJ, Shapiro G, Winer EP, Krop IE. A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer. Journal of Clinical Oncology. 32: 1106-1106. DOI: 10.1200/Jco.2014.32.15_Suppl.1106 |
0.355 |
|
| 2014 |
Paweletz CP, Oxnard GR, Kuang Y, O'Connell A, Yanagita M, Messineo MM, Kirschmeier P, English JM, Jackman DM, Jänne PA. Abstract 939: Serial monitoring ofEGFRmutations in plasma and matched tissue fromEGFRmutant non-small cell lung cancer patients on erlotinib Cancer Research. 74: 939-939. DOI: 10.1158/1538-7445.Am2014-939 |
0.531 |
|
| 2014 |
Palakurthi SS, Liu JF, Zeng Q, Zhou S, Ivanova E, Paweletz C, Murgo J, Evangelista J, Curtis J, Piao H, Gokhale P, English JM, Kirschmeier P, Wong K, Matulonis UA, et al. Abstract 1202: Patient derived xenograft model platform of high grade serous ovarian cancer supporting discovery of targeted therapies and biomarkers Cancer Research. 74: 1202-1202. DOI: 10.1158/1538-7445.Am2014-1202 |
0.418 |
|
| 2011 |
Nagashima K, Shumway SD, Sathyanarayanan S, Chen AH, Dolinski B, Xu Y, Keilhack H, Nguyen T, Wiznerowicz M, Li L, Lutterbach BA, Chi A, Paweletz C, Allison T, Yan Y, et al. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. The Journal of Biological Chemistry. 286: 6433-48. PMID 21118801 DOI: 10.1074/Jbc.M110.156463 |
0.363 |
|
| 2010 |
Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, ... ... Paweletz CP, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Science Translational Medicine. 2: 43ra55. PMID 20686178 DOI: 10.1126/Scitranslmed.3001065 |
0.365 |
|
| 2010 |
Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H, Jewell JP, Kariv I, Katz JD, Kunii K, Lu W, ... ... Paweletz CP, et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Research. 70: 1524-33. PMID 20145145 DOI: 10.1158/0008-5472.Can-09-2541 |
0.336 |
|
| 2010 |
Nagashima K, Shumway SD, Sathyanarayanan S, Chen A, Dolinski B, Xu Y, Keilhack H, Nguyen T, Wiznerowicz M, Li L, Lutterbach BA, Paweletz C, Allison T, Yan Y, Munshi SK, et al. Selective inhibition of PDK1 using an allosteric kinase inhibitor and RNAi impairs cancer cell migration and anchorage-independent growth of primary tumor lines Journal of Biological Chemistry. DOI: 10.2210/Pdb3Nay/Pdb |
0.376 |
|
| 2008 |
Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA, Li L, Gooden F, Korenchuk S, Hou XS, Harrington EA, Randolph S, Reilly JF, Ware CM, Kadin ME, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Research. 68: 3785-94. PMID 18483262 DOI: 10.1158/0008-5472.Can-07-6091 |
0.372 |
|
| 2006 |
Fantin VR, Loboda A, Roth JA, Paweletz C, Randolph S, Pierce JW, Harrington EA, Hendrickson RC, Reilly JF, Ware C, Kadin ME, Duvic M, Frankel SR, Richon VM. High Expression and Persistent Activation of STAT1, 3 and 5 Predicts Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Resistance in Cutaneous T-Cell Lymphoma Cells. Blood. 108: 4679-4679. DOI: 10.1182/Blood.V108.11.4679.4679 |
0.364 |
|
| 2003 |
Grubb RL, Calvert VS, Wulkuhle JD, Paweletz CP, Linehan WM, Phillips JL, Chuaqui R, Valasco A, Gillespie J, Emmert-Buck M, Liotta LA, Petricoin EF. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics. 3: 2142-6. PMID 14595813 DOI: 10.1002/Pmic.200300598 |
0.337 |
|
| 2003 |
Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF, Liotta L. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Advances in Experimental Medicine and Biology. 532: 59-68. PMID 12908550 DOI: 10.1007/978-1-4615-0081-0_7 |
0.356 |
|
| 2002 |
Krieg RC, Paweletz CP, Liotta LA, Petricoin EF. Clinical proteomics for cancer biomarker discovery and therapeutic targeting. Technology in Cancer Research & Treatment. 1: 263-72. PMID 12625785 DOI: 10.1177/153303460200100407 |
0.306 |
|
| 2001 |
Paweletz CP, Charboneau L, Liotta LA. Overview of metastasis assays Current Protocols in Cell Biology / Editorial Board, Juan S. Bonifacino ... [Et Al.]. Unit 19.1. PMID 18228344 DOI: 10.1002/0471143030.Cb1901S12 |
0.328 |
|
| 2001 |
Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EF. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Disease Markers. 17: 301-7. PMID 11790897 DOI: 10.1155/2001/674959 |
0.318 |
|
| 2001 |
Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, Petricoin EF. New approaches to proteomic analysis of breast cancer Proteomics. 1: 1205-1215. PMID 11721633 DOI: 10.1002/1615-9861(200110)1:10<1205::Aid-Prot1205>3.0.Co;2-X |
0.361 |
|
| 2001 |
Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin EF, Liotta LA. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front Oncogene. 20: 1981-1989. PMID 11360182 DOI: 10.1038/Sj.Onc.1204265 |
0.347 |
|
| 2001 |
Paweletz CP, Liotta LA, Petricoin EF. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics Urology. 57: 160-163. PMID 11295617 DOI: 10.1016/S0090-4295(00)00964-X |
0.368 |
|
| 2000 |
Simone NL, Paweletz CP, Charboneau L, Petricoin EF, Liotta LA. Laser capture microdissection: Beyond functional genomics to proteomics Molecular Diagnosis. 5: 301-307. PMID 11172494 DOI: 10.1007/Bf03262091 |
0.336 |
|
| 2000 |
Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF, Emmert-Buck MR. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis. 21: 2235-42. PMID 10892734 DOI: 10.1002/1522-2683(20000601)21:11<2235::Aid-Elps2235>3.0.Co;2-A |
0.333 |
|
| 2000 |
Emmert-Buck MR, Gillespie JW, Paweletz CP, Ornstein DK, Basrur V, Appella E, Wang QH, Huang J, Hu N, Taylor P, Petricoin EF. An approach to proteomic analysis of human tumors Molecular Carcinogenesis. 27: 158-165. PMID 10708477 DOI: 10.1002/(Sici)1098-2744(200003)27:3<158::Aid-Mc2>3.0.Co;2-2 |
0.355 |
|
| 2000 |
Paweletz CP, Gillespie JW, Ornstein DK, Simone NL, Brown MR, Cole KA, Wang QH, Huang J, Hu N, Yip TT, Rich WE, Kohn EC, Linehan WM, Weber T, Taylor P, et al. Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip Drug Development Research. 49: 34-42. DOI: 10.1002/(Sici)1098-2299(200001)49:1<34::Aid-Ddr6>3.0.Co;2-W |
0.347 |
|
| Show low-probability matches. |